NCT02711202 2026-04-13
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Institute for Clinical and Experimental Medicine
Phase NA Completed
Institute for Clinical and Experimental Medicine
Case Comprehensive Cancer Center
St. Jude Children's Research Hospital
Cellectis S.A.
Cellectis S.A.
Northwestern University